Racial/ethnic differences in drug disposition and response: review of recently approved drugs.
about
Pharmacokinetics and safety of ixazomib plus lenalidomide-dexamethasone in Asian patients with relapsed/refractory myeloma: a phase 1 studyA multicenter phase 2 study of pomalidomide plus dexamethasone in patients with relapsed and refractory multiple myeloma: the Japanese MM-011 trialEthnic sensitivity assessment of the antibody-drug conjugate trastuzumab emtansine (T-DM1) in patients with HER2-positive locally advanced or metastatic breast cancer.Assessment of ethnic differences in sunitinib outcome between Caucasian and Asian patients with metastatic renal cell carcinoma: a meta-analysis.Phase 1 study of ixazomib alone or combined with lenalidomide-dexamethasone in Japanese patients with relapsed/refractory multiple myeloma.Pharmacokinetics, Pharmacodynamics, Pharmacogenomics, Safety, and Tolerability of Avatrombopag in Healthy Japanese and White Subjects.Pharmacogenetic allele nomenclature: International workgroup recommendations for test result reporting.Submicroscopic carriage of Plasmodium falciparum and Plasmodium vivax in a low endemic area in Ethiopia where no parasitaemia was detected by microscopy or rapid diagnostic test.Distributive justice, diversity, and inclusion in precision medicine: what will success look like?Uterine fibroid shrinkage after short-term use of selective progesterone receptor modulator or gonadotropin-releasing hormone agonist.Continuous treatment with lenalidomide and low-dose dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma in Asia: subanalysis of the FIRST trial.Idelalisib for relapsed/refractory indolent B-cell non-Hodgkin's lymphoma: an overview of pharmacokinetics and clinical trial outcomes.New developments in the management of relapsed/refractory multiple myeloma - the role of ixazomib.Exploring public genomics data for population pharmacogenomicsToward Optimum Benefit-Risk and Reduced Access Lag For Cancer Drugs in Asia: A Global Development Framework Guided by Clinical Pharmacology Principles.Nurses' Use of Race in Clinical Decision Making.If We Would Only Ask: How Henrietta Lacks Continues to Teach Us About Perceptions of Research and Genetic Research Among African Americans Today.Safety of ixazomib for the treatment of multiple myeloma.Minorities Are Underrepresented in Clinical Trials of Pharmaceutical Agents for Cystic Fibrosis.Will Precision Medicine Move Us beyond Race?Pharmacodynamics, pharmacokinetics, and safety of ticagrelor in Chinese patients with stable coronary artery disease.From sexless to sexy: Why it is time for human genetics to consider and report analyses of sex.Pharmacokinetic considerations for use of artemisinin-based combination therapies against falciparum malaria in different ethnic populations.Global population pharmacokinetics of the investigational Aurora A kinase inhibitor alisertib in cancer patients: rationale for lower dosage in Asia.Are the Origins of Precision Medicine Found in the Corpus Hippocraticum?Pharmacokinetics of CYP2C9, CYP2C19, and CYP2D6 substrates in healthy Chinese and European subjects.Design of a 24-week trial of empagliflozin once daily in hypertensive black/African American patients with type 2 diabetes mellitus.Reverse Translation of US Food and Drug Administration Reviews of Oncology New Molecular Entities Approved in 2011-2017: Lessons Learned for Anticancer Drug Development.Leveraging the Learning Health Care Model to Improve Equity in the Age of Genomic Medicine.The clinical imperative for inclusivity: Race, ethnicity, and ancestry (REA) in genomicsDemographic Composition of Select Oncologic New Molecular Entities Approved by the FDA Between 2008 and 2017
P2860
Q33425607-5D55EA58-13A6-4519-B02C-90B69FAE21AEQ33431621-BCE00B96-3510-4685-9FFD-7F6D86120264Q33433942-C13E17C7-BC36-48AE-8D54-E437CC909C7AQ33437427-5F7EF298-F0CF-4E17-AF43-756B4B7D962FQ33437790-6D2CD71C-5499-4F38-873A-765D1939E9C7Q33440375-8139889E-3385-4927-867C-D9C8D0A45C11Q35812195-42ADAC8A-F4EA-4909-B750-2809C3CE31DAQ35913794-16264896-751B-4D74-ABB7-0A425229B6F7Q37624446-5C9CE8E6-263A-4A4E-A42D-9B82C6065D8AQ37647346-C9C113B0-54A0-4AD4-9AF0-3ACFE8261611Q37664019-624EE559-5ACA-4C6E-AF04-45175025EEC7Q38581826-C741166D-2CDF-4F81-9239-1986B4A30728Q38598891-CBA37279-7C01-42FB-88DB-71E78C7EDF75Q38644432-9BB05263-5FF2-458D-8B6E-72901C8D9A4DQ38719689-5A149704-53D0-4C8E-AA78-E520C0B64BFFQ39346976-32EA0DC0-5955-460B-81B2-DF189E0ACCABQ39355611-9B26962D-FA0F-46FF-A957-C9A0588D2C11Q39404809-6D1DACFE-49D2-4153-AAA7-8D71B2CD3911Q41631965-36EAC9A2-0EE7-42E9-93BB-ED8E361C3CA9Q41666847-3B8FA0F9-B23B-477E-91C1-37C6E46717FFQ42023858-AD15CDC6-42D4-44EF-A232-65FAD1751042Q42355531-459D9E55-7549-4E93-9FBF-8BC9706CCB16Q46405195-2F54CA27-9FE3-42B8-8F72-0A70B1E7475BQ47156672-A602EF75-DBDC-468A-9FDD-1378F1F02504Q47203284-62C0A671-8075-4668-A848-46DB894FB310Q47404372-F9354104-AE59-4A41-8B32-4D2F067EE059Q47594318-51922F0C-EA00-49C2-99CC-D9A2FE2B7443Q52740762-4CE01911-B25B-4059-90DA-4E3A9978EF0DQ53452251-B11765C4-4088-4CFA-AE09-A8D79EAC67E4Q57455595-93F89F24-CBE9-41BB-ADC6-A3B43FF04C91Q58697688-8ACA3B26-A227-4D40-A8DE-CB520217320F
P2860
Racial/ethnic differences in drug disposition and response: review of recently approved drugs.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Racial/ethnic differences in d ...... ew of recently approved drugs.
@en
type
label
Racial/ethnic differences in d ...... ew of recently approved drugs.
@en
prefLabel
Racial/ethnic differences in d ...... ew of recently approved drugs.
@en
P2093
P2860
P356
P1476
Racial/ethnic differences in d ...... ew of recently approved drugs.
@en
P2093
A Ramamoorthy
M A Pacanowski
P2860
P304
P356
10.1002/CPT.61
P407
P577
2015-01-20T00:00:00Z